A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
List view / Grid view
Filter the results
The European Commission has granted marketing authorisation to Stelara (ustekinumab) to treat patients aged six to 11 with moderate to severe plaque psoriasis.
Janssen has recently received marketing authorisation from the European Commission for Stelara to treat ulcerative colitis. Dr Jaime Oliver discusses the mode of action and why the treatment is needed.
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis.
The FDA has approved an expanded indication for Stelara for the treatment of adolescents with moderate plaque psoriasis...